Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 22Ovarian Neoplasms 18Lung Neoplasms 15Endometrial Neoplasms 15Triple Negative Breast Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 13Neoplasm Metastasis 10Fallopian Tube Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Esophageal Neoplasms 6Adenocarcinoma Of Esophagus 6Neoplasms 5Stomach Neoplasms 4Melanoma 4Esophageal Squamous Cell Carcinoma 4Cholangiocarcinoma 4Colorectal Neoplasms 3Carcinoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Peritoneal Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Brenner Tumor 2Anatomic Stage I Breast Cancer AJCC v8 2Advanced Solid Tumour 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma of Lung 2Adenocarcinoma 2

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced NUT Carcinoma × Paclitaxel × 30 days × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡